Markets
Will Utah's AI prescription refill program face state-level regulatory changes by August 31, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if any new state-level regulations specific to Utah's AI-driven prescription refill pilot program are officially enacted by August 31, 2026. This includes legislation, healthcare board policies, or executive actions aimed explicitly at modifying, expanding, or restricting the program. Public announcements or documented evidence of such changes will determine resolution.
Rules
- Market closes at 8/31/2026.
- Logic weighted resolution applies.
Current odds seem too low on this. Utah has been pushing innovation in healthcare, and the AI program aligns with that trend. However, regulatory scrutiny is likely given the complexities of AI in health. I'd expect at least some adjustments before the deadline, but maybe not drastic ones. Price might swing as more updates roll in.
Rationale:The comment provides a reasonable assessment of the situation, noting Utah's push for healthcare innovation and the potential for regulatory scrutiny, which is factually accurate. It avoids logical fallacies and remains relevant to the market question, though it could benefit from more specific data or examples. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the speculative nature of the comment.
Current odds are too low on this changing by August. States are slow to adapt to tech like this, and I don't see a significant trend pushing for changes in Utah specifically. However, if they see evidence of misuse or data issues, they might respond faster than expected.
Rationale:The comment provides a mostly accurate assessment of the slow pace of regulatory changes in response to technology, which is supported by general trends in state governance. It logically discusses potential factors that could influence regulatory changes, showing no significant logical fallacies. The relevance to the market question is strong, though it could benefit from more specific data or examples. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the speculative nature of the comment.
honestly, this market feels off. there’s a lot of chatter around healthcare regulations tightening, especially with AI stuff being so new and contentious. like, sure, utah’s been making strides with the program, but you can’t ignore the push from traditionalists who are wary of AI tweaking prescriptions. plus, states like california are already talking about more oversight. i’d say there’s at least a 65% chance of some changes before the deadline. seems like the price here doesn't really reflect that risk.
Rationale:The comment provides a mostly accurate assessment of the current regulatory climate surrounding AI in healthcare, particularly in relation to Utah's program, which supports a higher Fact Check score. It logically discusses the potential for regulatory changes, showing relevance to the market question. While there are some emotional elements, the argument remains grounded in reasoning, justifying a balanced score in Logic/Emotion. The weights reflect the importance of factual accuracy and logical coherence in this context.
the market is pricing this too low, given how states have been ramping up regulations on tech. Utah's program feels like it’s ripe for tweaks, especially with the ongoing debates about data privacy and safety. I wouldn't be surprised if we see some changes.
Rationale:The comment presents a reasonable perspective on the potential for regulatory changes in Utah's AI prescription refill program, linking it to broader trends in state regulations. While it lacks specific evidence to fully substantiate the claims, it is mostly accurate and relevant to the market question. The weights reflect a balance between the need for factual accuracy and the logical reasoning behind the predictions, with a slight emphasis on relevance due to the context of ongoing debates about data privacy and safety.
This feels too uncertain for the predicted outcome; state-level regulations can change quickly, and this seems like a risky bet.
Rationale:The comment expresses a valid concern about the uncertainty of state-level regulations, which is relevant to the market question. However, it lacks specific factual references to support the claim of uncertainty, leading to a slightly lower score in Fact Check. The comment is logically sound and free from fallacies, but it does rely somewhat on emotional appeal regarding the perceived risk of the bet. The weights reflect the importance of relevance and logical soundness in this context.
This feels way too uncertain rn. State-level changes could ramp up if there’s any pushback from pharmacies, but I’d think a solid majority won’t budge before August 31. I think the market should be closer to a 30% chance instead of whatever it's at now.
Rationale:The comment presents a reasonable perspective on the uncertainty surrounding state-level changes, which is relevant to the market question. However, it lacks specific evidence to support the claim about the majority of pharmacies not budging, leading to a slightly lower fact check score. The comment is mostly logical with some emotional elements, hence the balanced scores across the criteria.
I don't see major changes happening in that short timeframe. Seems like a low chance to me, market pricing feels off.
Rationale:The comment expresses a personal opinion about the likelihood of regulatory changes, which is mostly accurate but lacks specific evidence to support the claim. It is logically sound with no fallacies detected, and it is relevant to the market question, though it could benefit from more detailed reasoning. The weights reflect a balance between the need for factual support and the logical analysis of the market's pricing.
honestly, i’m not so sure about this one. the ai prescription refill program seemed solid when it launched, but states can be tricky with regulations. i’d expect some tweaks, especially with privacy concerns and potential pushback from pharmacists. the market’s got this priced pretty low, at like 30%. i don’t know, it feels like there’s a good chance it might hit roadblocks or at least some amendments. on the flip side, if they manage to work out a solid framework, it could roll out smoother than we think. either way, watching closely.
Rationale:The comment presents a mix of personal opinion and reasonable speculation about the potential regulatory changes affecting the AI prescription refill program. While it acknowledges the uncertainty and potential for amendments, it lacks specific factual references to support its claims, leading to a moderate score for Fact Check. The comment is relevant to the market question and avoids major logical fallacies, but it does lean slightly on emotional appeal regarding the uncertainty of the situation. The weights reflect the importance of relevance and logical reasoning in this context.
I just don't see the state making significant changes so quickly; it seems stable for now.
Rationale:The comment expresses a personal opinion about the stability of the state's regulatory environment, which is somewhat subjective and lacks specific evidence, leading to a score of 70 for Fact Check. There are no logical fallacies present, hence a high score in that category. The comment is relevant to the market question but does not provide detailed reasoning or data, resulting in moderate scores for Relevance and Logic/Emotion Balance. The weights reflect the need for factual accuracy and relevance in this context.
I think the price is off; while regulatory changes are possible, the momentum in favor of AI in healthcare seems to be stronger than ever, which makes me skeptical about significant changes in the near term.
Rationale:The comment presents a reasonable perspective on the potential for regulatory changes, acknowledging the possibility while emphasizing the current momentum for AI in healthcare. The factual accuracy is mostly sound, but lacks specific evidence to support the claims about momentum. The comment is relevant to the market question and avoids major logical fallacies, though it does lean slightly on emotional appeal regarding skepticism. The weights reflect the need for a balanced assessment of the comment's logical reasoning and relevance to the market question.